Clinical trial · Observational
Expression Analysis of the COPB 2 and Bcl-2 in Early Stages of Endometrial Carcinoma
A Study Without a Protocol Number. Documentation Filed in the Registry Under Number 01/19/1438. Date: 08.04.2019.
NCT05951426CI-TRIAL-00068079completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
COPB2 is a subunit of the intracellular transport system between cell organelles that participates in the regulation of cell division and differentiation. Bcl-2 is a protein that participates in regulating the process of apoptosis. Through the research,investigators tried to examine and establish the correlation of the expression of these two genes in endometrial cancer at an early stage.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Carcinoma Cellular Diagnosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- experimental group
- description
- 40 patients in whom Endometrial carcinoma was diagnosed as part of the experimental group.
- interventionNames
- Procedure: 1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage
- label
- control group
- description
- 20 patients in whom cancer or atypical hyperplasia of the endometrium was excluded histopathologically.
- interventionNames
- Procedure: 1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage
Primary outcomes (1)
- measure
- Relative expression COPB2 and BCL-2
- timeFrame
- The laboratory processing of the material lasted 3 months, after all the samples were collected during the clinical part of the research. In the period from 01.03. 2022-01.06.2022.
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * signed informed consent of the patient * pathohistological confirmation of endometrial carcinoma for the experimental group * normal endometrial tissue and hyperplasia simplex endometrii for the control group. Exclusion Criteria: * malignant disease in the patient whose treatment is still ongoing * pathohistological determination of atypical hyperplasia of the endometrial tissue
References
Publications (0)
Data not yet available
No reference posted for this study.